This consensus statement disseminated by the International Society for Heart and Lung Transplantation (ISHLT) focuses on the prevention and management of hemocompatability-related adverse events (HRAEs) in patients with durable, continuous-flow left ventricular assist devices (CF-LVAD). As survival in this group of patients continues to improve with advances in technology, HRAEs remain a concern. The ISHLT summarizes the literature in this field and shares several recommendations including management of antiplatelet agents, oral anticoagulation, management of high-risk patients, and management of bleeding or clotting events based on different existing devices.
You are here:
ISHLT Consensus Statement on Strategies to Prevent and Manage Hemocompatibility Related Adverse Events in VAD Patients
Submitted by: Mujtaba Mubashir
Source: The Journal of Heart and Lung Transplantation
Keywords:
Author(s): Ian B. Hollis, Douglas L. Jennings, Selim Krim, Van-Khue Ton, Anique Ducharme, Jennifer Cowger, Mary Looby, J.J. Eulert-Green, Neha Bansal, Ed Horn, Mirnela Byku, Jason Katz, C.J. Michaud, Indranee Rajapreyar, Patrick Campbell, Cassandra Vale,Richard Cosgrove, Jaime Hernandez-Montfort, Jessica Otero, Amanda Ingemi, Shashi Raj, Phillip Weeks, Richa Agarwal, Elena S. Martinez,Laurens F. Tops, Mustafa M. Ahmed, Amy Kiskaddon, Jamila Kremer, Mary Keebler, Ravi K. Ratnagiri
